MCID: CRD137
MIFTS: 41

Cardiogenic Shock

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Cardiogenic Shock

MalaCards integrated aliases for Cardiogenic Shock:

Name: Cardiogenic Shock 56
Shock, Cardiogenic 69
Shock Cardiogenic 52

Characteristics:

Orphanet epidemiological data:

56
cardiogenic shock
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

Orphanet 56 ORPHA97292
UMLS via Orphanet 70 C0036980
ICD10 via Orphanet 34 R57.0
ICD10 33 R57.0

Summaries for Cardiogenic Shock

MalaCards based summary : Cardiogenic Shock, also known as shock, cardiogenic, is related to inferior myocardial infarction and myocardial infarction, and has symptoms including syncope and shock without mention of trauma. An important gene associated with Cardiogenic Shock is NPPB (Natriuretic Peptide B), and among its related pathways/superpathways are Senescence and Autophagy in Cancer and amb2 Integrin signaling. The drugs Dobutamine and Heparin have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and liver.

Wikipedia : 72 Cardiogenic shock is a life-threatening medical condition resulting from an inadequate circulation of... more...

Related Diseases for Cardiogenic Shock

Diseases related to Cardiogenic Shock via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
id Related Disease Score Top Affiliating Genes
1 inferior myocardial infarction 29.8 PIK3C2A PLAT
2 myocardial infarction 29.7 ADM IL6 NPPB PIK3C2A PLAT
3 peripheral artery disease 28.5 IL6 NPPB PLAT
4 cardiac tamponade 11.3
5 ogden syndrome 11.0
6 acute myocardial infarction 10.6
7 cardiomyopathy 10.4
8 ophthalmia neonatorum 10.3 NPPB PIK3C2A
9 idiopathic juxtafoveal retinal telangiectasia 10.2 ADM NPPB
10 broad ligament malignant neoplasm 10.2 ADM NPPB
11 cardiac arrest 10.2
12 myocarditis 10.2
13 thrombosis 10.2
14 congenital nonspherocytic hemolytic anemia 10.2 IL6 NPPB
15 ventricular tachycardia, catecholaminergic polymorphic, 1 10.2 NPPB PIK3C2A
16 herpangina 10.2 IL6 NPPB
17 islet cell tumor 10.1 IL6 NPPB
18 virilizing ovarian tumor 10.1 IL6 PIK3C2A
19 pheochromocytoma 10.1
20 second-degree atrioventricular block 10.1 NPPB PIK3C2A
21 placental abruption 10.1 IL6 NPPB
22 epstein-barr virus hepatitis 10.1 IL6 PIK3C2A
23 pyelonephritis 10.1 NPPB PIK3C2A
24 intracranial arteriosclerosis 10.1 IL6 NPPB
25 left ventricular outflow tract obstruction 10.1
26 levator syndrome 10.1 IL6 NPPB
27 vogt-koyanagi-harada disease 10.1 IL6 PIK3C2A
28 pancreas lymphoma 10.0 IL6 NPPB
29 breast papillary carcinoma 10.0 ADM IL6
30 ostertagiasis 10.0 IL6 PIK3C2A
31 atrophy of prostate 10.0 IL6 PIK3C2A
32 coronary artery disease 10.0
33 artery disease 10.0
34 acute myocarditis 10.0
35 hypopharynx cancer 9.9 NPPB PLAT
36 barbiturate abuse 9.9 NPPB PLAT
37 atrioventricular block 9.9
38 endocarditis 9.9
39 periampullary adenoma 9.9 IL6 NPPB
40 dilated cardiomyopathy 9.9
41 hepatitis 9.9
42 phaeochromocytoma 9.9
43 myxedema 9.9
44 beriberi 9.9
45 ventricular septal defect 9.9
46 churg-strauss syndrome 9.9
47 giant cell myocarditis 9.9
48 aneurysm 9.9
49 chronic diarrhea due to guanylate cyclase 2c overactivity 9.8 IL6 PLAT
50 lung superior sulcus carcinoma 9.8 IL6 NPPB

Comorbidity relations with Cardiogenic Shock via Phenotypic Disease Network (PDN): (show all 19)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Cardiac Arrest
Chronic Kidney Failure Chronic Myocardial Ischemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Intermediate Coronary Syndrome
Ischemic Heart Disease Kidney Disease
Left Ventricular Outflow Tract Obstruction Mitral Valve Disease
Peripheral Vascular Disease Respiratory Failure
Third-Degree Atrioventricular Block Tricuspid Valve Disease
Ventricular Fibrillation, Familial, 1

Graphical network of the top 20 diseases related to Cardiogenic Shock:



Diseases related to Cardiogenic Shock

Symptoms & Phenotypes for Cardiogenic Shock

UMLS symptoms related to Cardiogenic Shock:


syncope, shock without mention of trauma

Drugs & Therapeutics for Cardiogenic Shock

Drugs for Cardiogenic Shock (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dobutamine Approved Phase 4,Phase 3,Phase 2 34368-04-2 36811
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
3
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
4
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
5
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
7
Abciximab Approved Phase 4 143653-53-6
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Everolimus Approved Phase 4 159351-69-6 6442177
10
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
11
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
12
Tenecteplase Approved Phase 4,Phase 2,Phase 3 191588-94-0
13 Racepinephrine Approved Phase 4,Phase 2
14
Furosemide Approved, Vet_approved Phase 4,Phase 3 54-31-9 3440
15
Milrinone Approved Phase 4 78415-72-2 4197
16
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
17 Simendan Investigational Phase 4,Phase 2,Phase 3 131741-08-7
18 Adrenergic Agents Phase 4,Phase 3,Phase 2
19 Adrenergic Agonists Phase 4,Phase 3,Phase 2
20 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
21 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
22 Vasodilator Agents Phase 4,Phase 2,Phase 3
23 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3
24 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
25 Anti-Bacterial Agents Phase 4
26 Anti-Infective Agents Phase 4,Phase 2
27 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3
28 Protective Agents Phase 4,Phase 3,Phase 2
29 Antibiotics, Antitubercular Phase 4
30 Autonomic Agents Phase 4,Phase 3,Phase 2
31 calcium heparin Phase 4,Phase 3,Phase 2
32 Atorvastatin Calcium Phase 4 134523-03-8
33 Analgesics Phase 4
34 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
35 Respiratory System Agents Phase 4,Phase 3,Phase 2
36 Central Nervous System Depressants Phase 4,Phase 2
37 Adrenergic alpha-2 Receptor Agonists Phase 4
38 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
39 Mydriatics Phase 4,Phase 2
40 Analgesics, Non-Narcotic Phase 4
41 Tissue Plasminogen Activator Phase 4,Phase 3
42 Anesthetics Phase 4
43 Anesthetics, Local Phase 4
44 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
45 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
46 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
47 Epinephryl borate Phase 4,Phase 2
48 Hypnotics and Sedatives Phase 4
49 Hypolipidemic Agents Phase 4
50 Immunoglobulin Fab Fragments Phase 4

Interventional clinical trials:

(show top 50) (show all 106)

id Name Status NCT ID Phase Drugs
1 Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Completed NCT01367743 Phase 4 epinephrine perfusion;norepinephrine perfusion
2 Intraaortic Balloon Pump in Cardiogenic Shock II Completed NCT00491036 Phase 4
3 Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock Completed NCT00420030 Phase 4 Abciximab
4 Efficacy Study of LV Assist Device to Treat Patients With Cardiogenic Shock (ISAR-SHOCK) Completed NCT00417378 Phase 4
5 Acute Chest Pain Treatment and Evaluation (ACTION) Study Completed NCT00434564 Phase 4
6 Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction. Completed NCT00324766 Phase 4 levosimendan;placebo,
7 Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial) Completed NCT02630290 Phase 4 Ropivacaine;Ropivacaine + Dexmedetomidine
8 Safety and Efficacy Study Comparing 3 New Types of Coronary Stents Completed NCT01166685 Phase 4
9 To Investigate the Role of Upstream High Dose Statin in STEMI Completed NCT01050348 Phase 4 Atorvastatin calcium;Inactive Placebo
10 Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) Completed NCT01634425 Phase 4
11 Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction Recruiting NCT02544594 Phase 4
12 ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock Recruiting NCT02301819 Phase 4
13 Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock Recruiting NCT01927549 Phase 4
14 Milrinone Versus Dobutamine in Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
15 Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive Recruiting NCT02531581 Phase 4 Furosemide;NaCl 9% isotonic
16 Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial. Active, not recruiting NCT01311700 Phase 4 Injectable (i.v.) metoprolol tartrate (up to 15 mg).
17 Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock Terminated NCT00314847 Phase 4
18 A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI) Terminated NCT00168792 Phase 4 Tenecteplase
19 Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery Unknown status NCT02361801 Phase 3 Liberal dobutamine protocol;Restrictive dobutamine protocol
20 Adjunctive Mild Hypothermia Therapy to Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated With Shock: A Feasibility Study Unknown status NCT00846222 Phase 3
21 Levosimendan Versus Dobutamine in Shock Patients Unknown status NCT00093301 Phase 2, Phase 3 Levosimendan;Dobutamine
22 Impact of Different Treatment in Multivessel Non ST Elevation Myocardial Infarction (NSTEMI) Patients: One Stage Versus Multistaged Percutaneous Coronary Intervention (PCI) Unknown status NCT01478984 Phase 3
23 Best Bypass Surgery (BBS) Trial Unknown status NCT00120991 Phase 3
24 Shock Trial: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. Completed NCT00000552 Phase 3 thrombolytic therapy
25 Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI) Completed NCT00251823 Phase 3 Eptifibatide facilitated PCI
26 The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study Completed NCT00882635 Phase 3 enoxaparin;Unfractionated heparin
27 Dopamine and Norepinephrine in Shock Patients Completed NCT00314704 Phase 3 dopamine versus norepinephrine
28 Which Therapy for Acute Heart Attacks? (The WEST Study) Completed NCT00121446 Phase 2, Phase 3 tenecteplase;enoxaparin;clopidogrel
29 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed NCT00623623 Phase 3 enoxaparin;tenecteplase;clopidogrel
30 REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) Completed NCT00640991 Phase 3 glulisine insulin, glargine insulin
31 Danish Cardiogenic Shock Trial Recruiting NCT01633502 Phase 3
32 Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock Recruiting NCT02633358 Phase 2, Phase 3
33 Bromocriptine in the Treatment of Peripartum Cardiomyopathy Recruiting NCT02590601 Phase 3 Bromocriptine
34 Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients Recruiting NCT02432976 Phase 2, Phase 3 Exenatide;Insulin
35 Effect of External Counter Pulsation on Ischemic Stroke Not yet recruiting NCT03075137 Phase 3
36 Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction Not yet recruiting NCT02905760 Phase 3 Furosemide;Placebo filling;Placebo furosemide;Vascular filling
37 A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack Terminated NCT00112281 Phase 3 Tilarginine Acetate Injection intravenous infusion
38 Clot Dissolving Treatment for Blood Clots in the Lungs Terminated NCT00680628 Phase 3 Tenecteplase + Enoxaparin;0.9% Saline + Enoxaparin
39 Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine Unknown status NCT01186783 Phase 2 ivabradine
40 Effects of Pyruvate in Patients With Cardiogenic Shock and Intra-aortic Balloon Counterpulsation Completed NCT00604331 Phase 2 Pyruvate
41 Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Recruiting NCT02591771 Phase 2 adrenaline
42 Exenatide for Myocardial Protection During Reperfusion Study Recruiting NCT01938235 Phase 2 Exenatide;Placebo
43 Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia Active, not recruiting NCT02841241 Phase 2 Esmolol
44 HEROIC (Heparin Requirement in Counterpulsation) Terminated NCT00445211 Phase 2 Heparin
45 The Melatonin Adjunct in the Acute myocaRdial Infarction Treated With Angioplasty Terminated NCT00640094 Phase 2 melatonin
46 Catheter Thrombectomy in Patients With Massive Pulmonary Embolism Terminated NCT00314002 Phase 1, Phase 2
47 The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients Terminated NCT00782652 Phase 2 inhaled nitric oxide;nitrogen gas
48 Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock Withdrawn NCT01901471 Phase 2 Single bolus of Placebo of CicloMulsion® (Neurovive).;Single bolus of cyclosporine A (CicloMulsion®, Neurovive)
49 Therapeutic Hypothermia for Severe Acute Pancreatitis Withdrawn NCT01794858 Phase 2
50 The Effect of Remote Ischemic Preconditioning in the Cardiac Surgery Completed NCT00997217 Phase 1

Search NIH Clinical Center for Cardiogenic Shock

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Cardiogenic Shock

Anatomical Context for Cardiogenic Shock

MalaCards organs/tissues related to Cardiogenic Shock:

39
Heart, Lung, Liver, Skeletal Muscle, Kidney, Monocytes, Tongue

Publications for Cardiogenic Shock

Articles related to Cardiogenic Shock:

(show top 50) (show all 696)
id Title Authors Year
1
Successful Use of Extracorporeal Membrane Oxygenation for the Treatment of Cardiogenic Shock due to Scorpion Envenomation. ( 28536661 )
2017
2
A dual therapy of off-pump temporary left ventricular extracorporeal device and amniotic stem cell for cardiogenic shock. ( 28882138 )
2017
3
Bridge to transplant or recovery in cardiogenic shock in a developing country. ( 28084085 )
2017
4
Levosimendan as a treatment for acute renal failure associated with cardiogenic shock after hip fracture. ( 28017176 )
2017
5
Temporary Mechanical Circulatory Support for Cardiogenic Shock. ( 28913740 )
2017
6
Trends in the Incidence and In-Hospital Outcomes of Cardiogenic Shock Complicating Thyroid Storm. ( 28864374 )
2017
7
Integrating invasive hemodynamic parameters into risk stratification of acute myocardial infarction and cardiogenic shock. ( 28891162 )
2017
8
Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. ( 28050899 )
2017
9
Advanced Percutaneous Mechanical Circulatory Support Devices for Cardiogenic Shock. ( 28857849 )
2017
10
Veno-arterial extracorporeal membrane oxygenation for severe cardiogenic shock secondary to phaeochromocytoma crisis. ( 28911298 )
2017
11
Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): theA need for a better definition of refractory cardiogenic shock. ( 28925084 )
2017
12
The prognostic value of MR-proadrenomedullin in patients with acute coronary syndrome complicated by cardiogenic shock. ( 27788594 )
2017
13
Utilization of the Impella for hemodynamic support during percutaneous intervention and cardiogenic shock: an insight. ( 28862481 )
2017
14
De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock. ( 28949061 )
2017
15
Acute Heart Failure Exacerbation with Cardiogenic Shock and Elevated Systemic Vascular Resistance Treated with a Combination of Nicardipine and Dobutamine Therapy. ( 28845316 )
2017
16
Acute Idiopathic Gastric Distension Causing Atrioventricular Block and Cardiogenic Shock. ( 28602457 )
2017
17
The Prognostic Risk Factors of ECMO in Patients with Cardiogenic Shock: A Retrospective Cohort Analysis. ( 28846533 )
2017
18
Prognostic Value of Relative Adrenal Insufficiency During Cardiogenic Shock: A Prospective Cohort Study With Long-Term Follow-Up. ( 27984534 )
2017
19
De-escalation of support with veno-arterial extracorporeal membrane oxygenation and Impella for cardiogenic shock: reply. ( 28948707 )
2017
20
Pledget Induced Cardiogenic Shock Following a Minimally Invasive Aortic Valve Replacement. ( 28850554 )
2017
21
Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. ( 28806755 )
2017
22
In-hospital outcomes of acute myocardial infarction with cardiogenic shock caused by right coronary artery occlusion vs. left coronary artery occlusion. ( 28918455 )
2017
23
Moving Beyond SHOCK: New Paradigms in the Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock. ( 28024554 )
2017
24
Triheptanoin: A Rescue Therapy for Cardiogenic Shock in Carnitine-acylcarnitine Translocase Deficiency. ( 28689308 )
2017
25
Left ventricular perforation after ImpellaAr placement in a patient with cardiogenic shock. ( 28944588 )
2017
26
Predictive value of SYNTAX score II for clinical outcomes in cardiogenic shock underwent primary percutaneous coronary intervention; a pilot study. ( 28889354 )
2017
27
Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. ( 28923988 )
2017
28
Incidence and risk factors of groin lymphocele formation after venoarterial extracorporeal membrane oxygenation in cardiogenic shock patients. ( 28822659 )
2017
29
A Case of Cardiogenic Shock Secondary to Complement-Mediated Myopericarditis From InfluenzaA BA Infection. ( 28844428 )
2017
30
Transvenous Inoue balloon aortic valvuloplasty with intra-aortic balloon pump in treating cardiogenic shock due to critical calcific aortic stenosis. ( 28044253 )
2017
31
Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. ( 28043661 )
2017
32
Early Initiation of Impella in Acute Myocardial Infarction Complicated byA Cardiogenic Shock Improves Survival: A Meta-Analysis. ( 28882288 )
2017
33
Reverse Takotsubo Cardiomyopathy and Cardiogenic Shock Associated With Methamphetamine Consumption. ( 28916123 )
2017
34
Effects of Additional Intra-aortic Balloon Counter-Pulsation Therapy to Cardiogenic Shock Patients Supported by Extra-corporeal Membranous Oxygenation. ( 27032984 )
2016
35
Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock. ( 27896787 )
2016
36
Shock Index More Sensitive Than Cardiogenic Shock in ST-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. ( 27980279 )
2016
37
Spontaneous, Postpartum Coronary Artery Dissection and Cardiogenic Shock with Extracorporeal Membrane Oxygenation Assisted Recovery in a 30-Year-Old Patient. ( 27127660 )
2016
38
Cardiogenic Shock as a Complication of Takotsubo Cardiomyopathy in a Patient With Incarcerated Bowel. ( 27590459 )
2016
39
Impact of intra-aortic balloon pump on short-term clinical outcomes in ST-elevation myocardial infarction complicated by cardiogenic shock: A "real life" single center experience. ( 27650459 )
2016
40
Device Strategies for Patients in INTERMACS Profiles 1 and 2 Cardiogenic Shock: Double Bridge With Extracorporeal Membrane Oxygenation and Initial Implant of More Durable Devices. ( 27658844 )
2016
41
Clinical outcomes of drug-eluting stents versus bare-metal stents in patients with cardiogenic shock complicating acute myocardial infarction. ( 27111168 )
2016
42
TCT-22 Dual Mechanical Support Combining Impella Microaxial Pump and Veno-arterial ECMO Rescues High-risk Patients in Refractory Cardiogenic Shock. ( 27970394 )
2016
43
Use of the Impella Device for Acute Coronary Syndrome Complicated by Cardiogenic Shock - Experience From a Single Heart Center With Analysis of Long-term Mortality. ( 27529657 )
2016
44
Follow-up Electrocardiograms in a Patient With Incarcerated Bowel-Triggered Takotsubo Syndrome Complicated by Cardiogenic Shock. ( 27998688 )
2016
45
Predictors of in-hospital mortality among cardiogenic shock patients. Prognostic and therapeutic implications. ( 27648979 )
2016
46
Associations with 30-day survival following extracorporeal membrane oxygenation in patients with acute ST segment elevation myocardial infarction and profound cardiogenic shock. ( 27601212 )
2016
47
Right-left ventricular interdependence: a promising predictor of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. ( 28011989 )
2016
48
Peroxiredoxin 1 induces inflammatory cytokine response and predicts outcome of cardiogenic shock patients necessitating extracorporeal membrane oxygenation: an observational cohort study and translational approach. ( 27142532 )
2016
49
Salvage myocardial revascularisation in spontaneous left main coronary artery dissection with cardiogenic shock - the role of mechanical circulatory support. ( 27625335 )
2016
50
Cardiogenic Shock From Coronary Compression: A Difficult Diagnosis But Easy Fix. ( 27000612 )
2016

Variations for Cardiogenic Shock

Expression for Cardiogenic Shock

Search GEO for disease gene expression data for Cardiogenic Shock.

Pathways for Cardiogenic Shock

Pathways related to Cardiogenic Shock according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.98 IL6 PLAT
2 10.3 IL6 PLAT

GO Terms for Cardiogenic Shock

Cellular components related to Cardiogenic Shock according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.26 ADM IL6 NPPB PLAT
2 cytoplasm GO:0005737 9.02 ADM IL6 NAA10 PIK3C2A PLAT

Biological processes related to Cardiogenic Shock according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to wounding GO:0009611 9.43 ADM IL6
2 response to insulin GO:0032868 9.4 ADM IL6
3 response to glucocorticoid GO:0051384 9.37 ADM IL6
4 response to cold GO:0009409 9.26 ADM IL6
5 platelet-derived growth factor receptor signaling pathway GO:0048008 9.16 PIK3C2A PLAT
6 response to calcium ion GO:0051592 9.02 IL6
7 response to lipopolysaccharide GO:0032496 8.96 ADM IL6
8 response to hypoxia GO:0001666 8.62 ADM PLAT

Molecular functions related to Cardiogenic Shock according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.96 ADM NPPB
2 receptor binding GO:0005102 8.92 ADM IL6 NPPB PLAT

Sources for Cardiogenic Shock

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....